when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ASTRAZENECA · news · pharmadog

← back to ASTRAZENECA

News mentioning ASTRAZENECA

363 stories

27dAstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerbiospace

27dSTAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studiesstat

27dSTAT+: Inhibrx claims first win for long-sought immunotherapy targetstat

27dAZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDfiercebiotech

27dFDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerfiercebiotech

27dBristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointfiercebiotech

28dAI will only revolutionize drug discovery and development if we play to its strengthsbiospace

28dInhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityfiercebiotech

28dRecon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, m...raps

28dFDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm voteendpoints

28dNovartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lillyendpoints

29dGuardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamahfiercebiotech

Sep 4, 26FDA Grants Accelerated Approval to a New Breast Cancer Treatmentfda press

Sep 4, 26This week in charts: China deals, stock flatlines and Lilly’s M&A spreebiopharma dive

Sep 4, 26Biotech is back, with H1 progress smoothing glide path through end of year: Truistbiospace

Sep 4, 26Menarini signs $771M deal to take Gan & Lee GLP-1 to European marketfiercebiotech

Sep 3, 26GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetfiercebiotech

Sep 2, 26UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapyendpoints

Sep 2, 26STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and morestat

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Sep 2, 26Novartis inks $3.2B subcutaneous drug delivery deal with Alteogenfiercebiotech

Sep 2, 26Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsbiospace

Sep 1, 26STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and morestat

Sep 1, 26ArsenalBio sheds most of staff in pivot to in vivo CAR-Tfiercebiotech

Aug 31, 26STAT+: Trump strikes nine more deals with drugmakers to lower pricesstat

Aug 31, 26STAT+: Can buying a drug patent application be seen as a bid to prolong a monopoly?stat

Aug 31, 26ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsybiopharma dive

Aug 31, 26ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CMfiercebiotech

Aug 31, 26STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and morestat

Aug 31, 26STAT+: Can a pregnancy hormone steer a cardiovascular treatment?stat

← prevpage 4 of 13next →